Indivior Pharmaceuticals (INDV) Research & Development (2024 - 2026)

Indivior Pharmaceuticals' Research & Development history runs 3 years deep, the most recent figure standing at $16.0 million for Q1 2026.

• On a quarterly basis, Research & Development fell 27.27% year-over-year to $16.0 million in Q1 2026; TTM through Mar 2026 was $91.0 million, a 9.9% decrease from a year earlier, with the FY2025 full-year figure at $97.0 million, down 9.35% from the prior year.
• Research & Development fell to $16.0 million in Q1 2026 per INDV's latest filing, from $21.0 million in the prior quarter.
• Across five years, Research & Development topped out at $33.0 million in Q3 2025 and bottomed at $16.0 million in Q1 2026.
• The 3-year median for Research & Development is $22.0 million (2024), against an average of $24.4 million.
• Biggest YoY gain for Research & Development was 50.0% in 2025; the steepest drop was 32.26% in 2025.
• Year by year, Research & Development stood at $31.0 million in 2024, then plunged by 32.26% to $21.0 million in 2025, then declined by 23.81% to $16.0 million in 2026.
• Per Business Quant, the three latest INDV Research & Development figures stand at $16.0 million (Q1 2026), $21.0 million (Q4 2025), and $33.0 million (Q3 2025).